Induction of tolerance after combined immunosuppression and -adsorption in two patients with acquired haemophilia after severe haemorrhages controlled by sequential administration of rFVIIa and FEIBA

Thrombosis and Haemostasis

Volumn 101, Issue 3, 2009, Pages 586-590

  Stockschiäder, Marcus ^a,b   Ruf, Leilani ^a   Linderer, Anne ^a   Schroeder, Thomas ^a   Knoefel, Wolfram T ^a   Haas, Rainer ^a   Giers, Günther ^a   Gerhardt, Andrea ^a   Sucker, Christoph ^a   Zotz, Rainer B ^a   Scharf, Rüdiger E ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BETA INTERFERON; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 INHIBITOR; CYCLOPHOSPHAMIDE; PREDNISONE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RITUXIMAB;

ADULT; ARTICLE; BLEEDING; CASE REPORT; DRUG MEGADOSE; HEMOPHILIA; HUMAN; IMMUNOADSORPTION; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL;

ADRENAL CORTEX HORMONES; ANTIBODIES, MONOCLONAL; BLOOD COAGULATION FACTORS; DRUG COMBINATIONS; FACTOR VIIA; HEMOPHILIA A; HEMORRHAGE; HUMANS; IMMUNE TOLERANCE; IMMUNOSORBENT TECHNIQUES; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS;

EID: 62549118233     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH08-11-0716     Document Type: Article

References (40)

1. Gilles JG, Jacquemin MG, Saint-Remy JM. Factor VIII inhibitors. Throrab Haemost 1997; 78: 641-646.
2. Cohen AJ, Kessler CM. Acquired inhibitors. Bail-Heres Clin Haematol 1996; 9: 331-354.
3. Sallah S, Wan JY. Inhibitors against factor VIII in patients with cancer. Analysis of 41 patients. Cancer 2001; 91: 1067-4074.
4. Hauser I, Schneider B, Lechner K. Post-partum factor VIII inhibitors. A review of the literature with special reference to the value of steroid and immunosuppressive treatment. Throrab Haemost 1995; 73: 1-5.
5. Collins PW, Hirsch S, Baglin TP. et al. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation. Blood 2007; 109: 1870-1877.
6. Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to Factor VIII. Thromb Haemost 1981; 45: 200-203.
7. Morrison AE, Ludlam CA, Kessler C. Use of porcine factor VIII in the treatment of patients with acquired hemophilia. Blood 1993; 81: 1513-1520.
8. Delgado .1, Jimenez-Yuste V, Hernandez-Navarro F, et al. Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors. Br J Haematol 2003; 121: 21-35.
9. Biggs R, Austen DE, Denson KW, et al. The mode of action of antibodies which destroy factor VIII. II. Antibodies which give complex concentration graphs. Br J Haematol 1972; 23: 137-155.
10. Brackmann HH, Oldenburg J, Schwaab R. Immune tolerance for the treatment of factor VIII inhibitors-twenty years' 'bonn protocol'. Vox Sang 1996; 70 (Suppl 1): 30-35.
11. Negrier C, Goudemand J, Sultan Y et al. Multi-center retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity. Thromb Haemost 1997; 77: 1113-1119.
12. Sallah S. Treatment of acquired haemophilia with factor eight inhibitor bypassing activity. Haemophilia 2004; 10: 169-173.
13. Ehrlich HJ, Henzl MJ, Gomperts ED. Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events. Haemophilia 2002; 8: 83-90.
14. Parameswaran R, Shapiro AD, Gill JC, et al. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry. Haemophilia 2005; 11: 100-106.
15. Astermark J, Donfield SM, DiMichele DM, et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA Novo-Seven Comparative (FENOC) Study. Blood 2007; 109: 546-551.
16. Hay CR, Negrier C, Eudlam CA. The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: a multicentre study. Thromb Haemost 1997; 78: 1463-1467.
17. Guillet B, Pinganaud C, Proulle V, et al. Myocardial infarction occurring in a case of acquired haemophilia during the treatment course with recombinant activated factor VII. Thromb Haemost 2002; 88: 698-699.
18. Hedner U, Erhardtsen E. Potential role of recombinant factor VIIa as a hemostatic agent. Clin Adv Hematol Oncol 2003; 1: 112-119.
19. Astermark J, Donfield SM, DiMichele DM, et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA Novo-Seven Comparative (FENOC) Study. Blood 2007; 109: 546-551.
20. Hoffman M, Monroe DM, III. The action of highdose factor VIIa (FVIIa) in a cell-based model of hemostasis. Dis Mon 2003; 49: 14-21.
21. Turecek PL, Varadi K, Gritsch H, et al. FEIBA: mode of action. Haemophilia 2004; 10 (Suppl 2): 3-9.
22. Key NS, Christie B, Henderson N, et al. Possible synergy between recombinant factor VIIa and prothrombin complex concentrate in hemophilia therapy. Thromb Haemost 2002; 88: 60-65.
23. Schneiderman J, Rubin E, Nugent DJ, et al. Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experience. Haemophilia 2007; 13: 244-248.
24. Rosenfeld SB, Watkinson KK, Thompson BH, et al. Pulmonary embolism after sequential use of recombinant factor VIIa and activated prothrombin complex concentrate in a factor VIII inhibitor patient. Thromb Haemost 2002; 87: 925-926.
25. Bui JD, Despotis GD, Trulock EP, et al. Fatal thrombosis after administration of activated prothrombin complex concentrates in a patient supported by extracorporeal membrane oxygenation who had received activated recombinant factor VII. J Thorac Cardiovasc Surg 2002; 124: 852-854.
26. Knobl P. Derfler K Extracorporeal immunoadsorption for the treatment of haemophilic patients with inhibitors to factor VIII or IX. Vox Sang 1999; 77 (Suppl 1): 57-64.
27. Huguet HC, Lasne D. Rothschild C, et al. Extracorporeal adsorption of anti-factor VIII allo-antibodies on randomly functionalized polystyrene resins. Thromb Haemost 2004; 91: 259-266.
28. Zeitler H, Ulrich-Merzenich G, Hess L, et al. Treatment of acquired hemophilia by the Bonn-Malmo Protocol: documentation of an in vivo immunomodulating concept. Blood 2005; 105: 2287-2293.
29. Knobl P. Derfler K, Korninger L, et al. Elimination of acquired factor VIII antibodies by extracorporal antibody-based immunoadsorption (Ig-Therasorb). Thromb Haemost 1995; 74: 1035-1038.
30. Rivard GE, St Louis J, Lacroix S, et al. Immunoadsorption for coagulation factor inhibitors: a retrospective critical appraisal of 10 consecutive cases from a single institution. Haemophilia 2003; 9: 711-716.
31. Watt RM, Bunitsky K, Faulkner EB, et al. Treatment of congenital and acquired hemophilia patients by extracorporeal removal of antibodies to coagulation factors: a review of US clinical studies 1987-1990. Hemophilia Study Group. Transfus Sci 1992; 13: 233-253.
32. Jansen M, Schmaldienst S, Banyai S, et al. Treatment of coagulation inhibitors with extracorporeal immunoadsorption (Ig-Therasorb). Br J Haematol 2001; 112:91-97.
33. Giorslrup P. Berntorp E, Larsson L, et al. Kinetic aspects of the removal of IgG and inhibitors in hemophiliacs using protein A immunoadsotption. Vox Sang 1991; 61:244-250.
34. Saint-Remy JM. Hemophilia factor VIII therapy. B-and T-cell tolerance: from basic concepts to clinical practice. Haematologica 2000; 85: 93-96.
35. Brackmann HH, Schwaab R, Effenberger W, et al. Antibodies to factor VIII in hemophilia A patients. Vox Sang 2000; 78 (Suppl 2): 187-190.
36. Onitilo AA, Skorupa A, Lal A, et al. Rituximab in the treatment of acquired factor VIII inhibitors. Thromb Haemost 2006; 96: 84-87.
37. Grillo-Lopez AJ, Hedrick E, Rashford M, et al. Rituximab: ongoing and future clinical development. Semin Oncol 2002; 29: 105-112.
38. Cartron G, Watier H, Golay J, et al. From the bench to the bedside: ways to improve rituximab efficacy. Blood 2004; 104: 2635-2642.
39. Fischer KG, Deschler B, Lubbert M. Acquired high-titer factor VIII inhibitor: fatal bleeding despite multimodal treatment including rituximab preceded by multiple plasmaphereses. Blood 2003; 101: 3753-3754.
40. Stasi R, Brunetti M, Stipa E, et al. Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia. Blood 2004; 103: 4424-4428.